The first of two phase III trials seeking to prove Spectrum Pharmaceuticals Inc.'s Rolontis (eflapegrastim) noninferior to Neulasta (pegfilgrastim) for chemotherapy-induced neutropenia management achieved that goal, validating the company's decision to license the drug from Hanmi Pharmaceutical Co. Ltd. in 2014.